Publisher
Springer Science and Business Media LLC
Reference92 articles.
1. Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 2019;54(2):407–19.
2. Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–19.
3. Hui E. Immune checkpoint inhibitors. J Cell Biol. 2019;218(3):740–1.
4. Cancer Care Ontario. Immune Checkpoint Inhibitor Toxicity Management Clinical Practice Guideline. Updated March 2018 [cited 10 Dec 2020]. https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/52976. Accessed 10 Dec 2020.
5. Horrow JC, Digregorio GJ, Barbieri EJ, Rupp E. Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible. Crit Care Med. 1990;18(8):858–61.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献